Genetics and MRD for therapy allocation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Josep-Maria Ribera, Anna Torrent, Mireia Morgades...
https://pubmed.ncbi.nlm.nih.gov/42081455/Actively Recruiting
Led by PETHEMA Foundation · Updated on 2022-02-18
300
Participants Needed
108
Research Sites
13 weeks
Total Duration
Researchers are studying adults aged 18 to 60 years with Philadelphia chromosome-negative acute lymphoblastic leukemia Ph-negative ALL. The study evaluates treatment outcomes based on measurable residual disease MRD status and genetic testing done at the start. The goal is to tailor therapy after initial consolidation to improve survival and remission rates. Patients initially receive a four-drug induction chemotherapy regimen including vincristine, prednisone, pegylated asparaginase, and daunorubicin. Those who do not respond may receive a second induction with fludarabine, cytarabine, G-CSF, and idarubicin. Patients with good MRD clearance and favorable genetics continue with early and delayed consolidation, reinduction, and maintenance chemotherapy using pediatric-type protocols. Others may proceed to allogeneic hematopoietic stem cell transplantation alloHSCT. Participants will undergo regular assessments of MRD after induction and consolidation phases, along with monitoring for complete remission at 4 to 8 weeks. Researchers will track overall survival for 3 years. Safety and treatment responses are evaluated throughout, with ongoing follow-up. The total study duration includes treatment periods and observation to assess long-term outcomes under the guidance of the PETHEMA Foundation.
CONDITIONS
Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults
J
Josep Maria Ribera, Ph
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
PETHEMA Foundation
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to several months based on treatment phases
Participants receive pediatric-type chemotherapy including induction, early and delayed consolidation, reinduction, and maintenance phases. Resistant participants may receive a second induction or proceed to allogeneic HSCT depending on treatment response and genetic results.
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Josep-Maria Ribera, Anna Torrent, Mireia Morgades...
https://pubmed.ncbi.nlm.nih.gov/42081455/PETHEMA Foundation
Lead Sponsor